Nexalin Technology (NXL) Projected to Post Earnings on Wednesday

Nexalin Technology (NASDAQ:NXL) is anticipated to release its results before the market opens on Wednesday, February 25th. Analysts expect Nexalin Technology to post earnings of ($0.12) per share and revenue of $0.08 million for the quarter.

Nexalin Technology Stock Up 8.6%

NXL stock opened at $0.50 on Monday. The company’s 50-day moving average price is $0.62 and its two-hundred day moving average price is $0.91. The firm has a market cap of $9.29 million, a P/E ratio of -0.75 and a beta of 3.95. Nexalin Technology has a 12 month low of $0.37 and a 12 month high of $3.28.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Susquehanna International Group LLP acquired a new stake in shares of Nexalin Technology during the third quarter valued at about $57,000. Renaissance Technologies LLC raised its stake in shares of Nexalin Technology by 119.2% during the fourth quarter. Renaissance Technologies LLC now owns 122,100 shares of the company’s stock valued at $68,000 after acquiring an additional 66,400 shares during the last quarter. Geode Capital Management LLC increased its holdings in Nexalin Technology by 23.4% in the fourth quarter. Geode Capital Management LLC now owns 150,274 shares of the company’s stock valued at $84,000 after purchasing an additional 28,454 shares during the period. Finally, PEAK6 LLC bought a new position in Nexalin Technology during the 4th quarter worth $266,000. 0.65% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on NXL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Nexalin Technology in a research note on Monday, December 29th. Wall Street Zen downgraded Nexalin Technology from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $5.00.

Nexalin Technology Company Profile

Nexalin Technology, Inc is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S.